Primary Hyperoxaluria Type 1 (PH1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Primary
Hyperoxaluria Type 1 (PH1) Market Outlook
Thelansis’s “Primary
Hyperoxaluria Type 1 (PH1) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2026 To 2036” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria Type 1 (PH1) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Primary
Hyperoxaluria Type 1 (PH1) Overview
Primary hyperoxaluria type 1 (PH1) is
a rare, autosomal recessive metabolic disorder caused by AGXT gene
mutations, which deplete hepatic peroxisomal alanine-glyoxylate
aminotransferase. This deficiency halts glyoxylate detoxification, driving
massive hepatic oxalate overproduction. When this burden overwhelms renal
excretion, calcium oxalate crystals precipitate in the kidneys, causing
recurrent stones, nephrocalcinosis, and renal failure. As kidney
function drops, systemic oxalosis occurs, where crystals infiltrate the
bones, eyes, and heart with devastating effects. While childhood
urolithiasis is classic, diagnosis relies on plasma or urinary oxalate metrics
and genetic testing, completely bypassing obsolete liver biopsies. Conventional
support uses high fluid intake and pyridoxine (Vitamin B6) for responsive
variants, but the modern therapeutic landscape centers on targeted RNA
interference. Crucially, lumasiran silences HAO1 to inhibit
glycolate oxidase, whereas nedosiran targets LDHA to block the
final conversion of glyoxylate to oxalate. These highly effective RNAi tools
have drastically lowered oxalate levels, shifting the surgical paradigm away
from aggressive liver-kidney transplants toward isolated kidney transplants
when necessary. Early diagnosis and proactive RNAi positioning now secure a
highly favorable prognosis by preventing irreversible systemic damage.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment